Officials at Cytiva say the company will work with Entos Pharmaceuticals to optimize a clinical manufacturing solution for the company’s Covigenix COVID-19 DNA vaccine candidate. Entos develops next generation nucleic acid medicines using its Fusogenix platform, which uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells, according to a Cytiva spokesperson.
